Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E18.79 EPS (ttm)3.34 Insider Own0.10% Shs Outstand1.62B Perf Week5.06%
Market Cap101.34B Forward P/E11.13 EPS next Y5.64 Insider Trans-6.77% Shs Float1.60B Perf Month2.47%
Income5.48B PEG1.15 EPS next Q1.20 Inst Own70.90% Short Float1.76% Perf Quarter15.94%
Sales23.78B P/S4.26 EPS this Y185.20% Inst Trans-0.04% Short Ratio3.71 Perf Half Y6.12%
Book/sh2.87 P/B21.85 EPS next Y18.30% ROA10.20% Target Price71.06 Perf Year-2.32%
Cash/sh5.32 P/C11.78 EPS next 5Y16.40% ROE115.60% 52W Range44.55 - 69.54 Perf YTD8.00%
Dividend2.28 P/FCF24.49 EPS past 5Y3.50% ROI16.90% 52W High-9.82% Beta1.48
Dividend %3.64% Quick Ratio1.40 Sales past 5Y7.90% Gross Margin79.80% 52W Low40.76% ATR1.32
Employees28000 Current Ratio1.60 Sales Q/Q18.20% Oper. Margin34.20% RSI (14)61.30 Volatility1.77% 2.06%
OptionableYes Debt/Eq6.87 EPS Q/Q31.10% Profit Margin23.00% Rel Volume0.76 Prev Close61.90
ShortableYes LT Debt/Eq6.35 EarningsApr 28 BMO Payout64.30% Avg Volume7.58M Price62.71
Recom2.20 SMA201.93% SMA505.15% SMA2009.21% Volume5,767,645 Change1.31%
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-30-16 09:22AM  Biogen & AbbVie's Multiple Sclerosis Drug Gets FDA Nod
May-28-16 02:52PM  Five Dividend Stocks Hedge Funds Love at Insider Monkey
08:30AM  3 Stories To Watch At The Years Biggest Cancer Conference
May-27-16 10:41PM  [$$] Once-Monthly MS Injection Approved in U.S. at The Wall Street Journal
09:38PM  Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA (daclizumab) for Multiple Sclerosis PR Newswire
09:36PM  Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA (Daclizumab) for Multiple Sclerosis Business Wire
06:43PM  Biogen, AbbVie once-monthly MS injection wins U.S. approval Reuters
06:19PM  Biogen, AbbVie once-monthly MS injection wins U.S. FDA approval Reuters
04:16PM  How Do Allergans Valuations Compare to Its Peers?
11:07AM  Inside Bristol-Myers Squibbs Virology Segment
09:15AM  Morning Technical Breakdown Highlights on Big Drug Makers Stocks
07:51AM  AbbVie's HUMIRA Gets EU Regulator's Positive Opinion To Treat Some Non-Infectious Uveities Types
07:00AM  AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision PR Newswire
May-26-16 01:58PM  Investors Eager for Gilead to Make Big Moves
09:30AM  The Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie
08:00AM  AbbVie to Present at the Jefferies 2016 Healthcare Conference PR Newswire
May-25-16 03:02PM  Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
10:05AM  4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends at 24/7 Wall St.
10:00AM  AbbVie/Boehringer Report Crohn's Disease Drug Interim Data
08:15AM  Short Sellers Take Mixed Stance on Major Pharma at 24/7 Wall St.
May-24-16 06:28PM  Richard Bernstein: Why Nobody Wants to Play
05:30PM  [$$] Gilead Names New Operating Chief at The Wall Street Journal
05:10PM  Incyte Guidance on Jakafi Sends Stock High
04:40PM  AbbVies Newly Licensed Drug Scores Against Crohns Disease
11:00AM  IL-23 Inhibitor Risankizumab Induces Remission in Phase II Study in Patients with Moderate-to-Severe Crohn's Disease PR Newswire
08:06AM  3 Stocks With Better Dividends Than Johnson & Johnson at Motley Fool
06:00AM  'Mad Money' Lightning Round: CVS Is a Buy, Buy, Buy
06:00AM  Innovus Pharma Joins AbbVie Inc. and Eli Lilly & Co. in the Race for the $3 Billion Testosterone Replacement Market Marketwired
May-23-16 06:02AM  CF Industries Pulls $8 Billion Takeover of OCI Assets
05:55AM  A Rudderless Market
May-21-16 03:31PM  Huawei Building Way to Live Forever: in the Matrix at Investopedia
May-20-16 03:41PM  A Heavy Hitter Just Stepped Up to the Cystic Fibrosis Plate at Motley Fool
01:20PM  Billionaire Larry Robbins Top Healthcare Picks for Q2 at Insider Monkey
08:11AM  AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : May 20, 2016
May-19-16 12:32PM  AbbVie To Present 13 Absracts In Inflammatory Bowel Diseases At Digestive Disease Week Annual Meeting
08:59AM  Specialty Drugs Added $87 More To Each Enrollee's Tab, Blue Cross Says at Forbes
08:39AM  Interest Rate Concerns Lead to Market Losses: How Did XLV React?
08:00AM  AbbVie's Leadership in Gastroenterology Showcased at Digestive Disease Week® with New HUMIRA® (adalimumab) Long-Term, Real-World Research and Promising Anti-IL-23 Antibody Late-Breaking Data PR Newswire
May-18-16 07:07PM  Will Mercks Recent New Developments Make a Difference?
05:00PM  AbbVie Demonstrates Progress in Oncology Research at ASCO 2016 Annual Meeting with Multiple Abstracts Evaluating Eight Medicines Across Cancer Types PR Newswire
03:40PM  4 Top Stocks in the Growing Medical Marijuana Industry
09:30AM  PharMerica, AbbVie, Red Robin Gourmet Burgers, Habit Restaurants and Shake Shack highlighted as Zacks Bull and Bear of the Day
09:26AM  4 Best Stocks in the Thriving Medical Marijuana Industry at TheStreet
09:16AM  Bear of the Day: AbbVie (ABBV)
May-17-16 04:20PM  US STOCKS-Wall St sells off amid Fed rate hike jitters
04:06PM  AbbVies Biggest Drug Gets Patent Setback; Stock Tumbles
04:06PM  AbbVies Biggest Drug Gets Patent Setback; Stock Tumbles at Investor's Business Daily
03:35PM  AbbVie's Patent Dam Springs a Leak at Bloomberg
03:07PM  Home Depot earnings can't turn Dow around as stocks sell off
03:02PM  [$$] Patent Office to Review a Regimen of AbbVie's Humira at The Wall Street Journal
02:52PM  US STOCKS-Wall St sells off as rate hike expectations rise Reuters
12:03PM  Why AbbVie (ABBV) Stock Is Down Today at TheStreet
11:26AM  Why AbbVie is Getting Hammered at Barrons.com
11:12AM  Coherus says U.S. Patent Office to review AbbVie's Humira Reuters
10:52AM  AbbVie Slides as U.S. Agency Questions Humira Patent at Bloomberg
May-16-16 01:14PM  Pfizer to buy Peninsula drug developer for $5.2 billion in latest Bay Area M&A at American City Business Journals
May-15-16 04:50PM  5 Stocks We're Watching but Not Buying Yet at Motley Fool
May-14-16 07:37PM  3 Cheap Stocks Set To Double Their Dividends at Forbes
06:40AM  5 Growth Stocks to Buy in May at Motley Fool
May-13-16 12:36PM  High-grade volumes surge past half trillion mark Reuters
09:30AM  The Zacks Analyst Blog Highlights: Medivation, Juno, Kite, ARIAD and AbbVie Zacks
08:01AM  Trending Now: ABBV Yahoo Finance - Qwiki
May-12-16 05:46PM  MSCI announces changes to U.S., China, emerging market indexes Reuters
05:43PM  Bristol-Myers/AbbVie Empliciti Gets Approved in the EU Zacks
04:40PM  Why June Could Be a Big Month for AbbVie Investors at Motley Fool
04:30PM  AbbVie to Present at the UBS Global Health Care Conference PR Newswire
01:04PM  ABBVIE INC. Financials EDGAR Online Financials
12:13PM  Inside XBI Large-Caps: European Commission Approves of Empliciti Market Realist
12:07PM  Biotech Stock Roundup: Medivation Buyout Rumors Continue, NewLink Plunges on Late-Stage Data Zacks
09:38AM  ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
09:07AM  Behind Gilead Sciences Pricing Pressures for HCV Drugs in the US Market Realist
08:00AM  Pharma's Game of (Hep C) Thrones at Bloomberg
07:59AM  New Strong Sell Stocks for May 12th Zacks
07:40AM  ASCO Could Make or Break These 7 Cancer Drug Trials at 24/7 Wall St.
04:05AM  How Will Rova-T Affect AbbVies Future Sales? Market Realist
03:05AM  Imbruvica Continues to Expand across Indications and Lines of Therapy Market Realist
May-11-16 02:25PM  Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Adult Patients Who Have Received at Least One Prior Therapy Business Wire
10:03AM  Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY Zacks
10:00AM  An ETF For Harnessing Dividend Growth at Forbes
08:45AM  Major Pharma Short Interest Continues to Recede at 24/7 Wall St.
May-10-16 04:50PM  Why Celgene Is Trading at a Premium Compared to Its Peers Market Realist
04:37PM  ABBVIE INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
04:21PM  Do Sluggish Sales of Harvoni Make Gilead Sciences a "Sell"? at Motley Fool
08:18AM  J&J, AbbVie Are Leading Biggest Global Borrowing Binge in Months at Bloomberg
05:06AM  How AbbVie Plans to Strengthen Its Position in Oncology Market Realist
04:06AM  AbbVie Reports Good Results for Next Generation HCV Regimen in 1Q16 Market Realist
May-09-16 10:18AM  Gilead Sciences: A Black Box of Uncertainty? at Barrons.com
07:30AM  U.S. FDA Expands IMBRUVICA® (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients PR Newswire
May-06-16 05:34PM  ABBVIE INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
02:40PM  Why Gilead Sciences Is Trading at a Discount Compared to Peers Market Realist
02:40PM  The Word on the Street: What Analysts Are Recommending for Gilead Sciences Now Market Realist
12:25PM  ABBVIE INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
09:15AM  New Strong Sell Stocks for May 6th Zacks
12:11AM  [$$] Knockoffs of Biotech Drugs Bring Paltry Savings at The Wall Street Journal
May-05-16 05:13PM  Charts are bullish for health care: Technician Yahoo Finance
10:28AM  [$$] Biotech Drug Knockoffs Bring Paltry Savings at The Wall Street Journal
May-04-16 08:41PM  Sohn Investment Conference 2016 Full Wrap Up Yahoo Finance Contributors
01:11PM  Biotech Stock Roundup: Amgen Impresses, Gilead Disappoints in Q1, Biogen to Spin Off Hemophilia Zacks
10:05AM  Gilead Sciences: Feeling the Competitive Burn? at Barrons.com
May-03-16 01:40PM  What Do Analysts Recommend for AbbVie? Market Realist
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics, Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, and Alvine Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GONZALEZ RICHARD AChairman of the Board and CEOMay 11Sale63.8039,0002,488,200338,421May 13 05:11 PM
HURWICH THOMAS A.VP, ControllerMay 10Option Exercise27.296,000163,74068,204May 12 05:44 PM
ALBAN CARLOSEVP, Commercial OperationsMay 10Sale63.5247,4383,013,262149,444May 12 05:39 PM
HURWICH THOMAS A.VP, ControllerMay 10Sale63.596,000381,54162,204May 12 05:44 PM
Schumacher Laura JExecutive Vice PresidentMar 08Sale56.0925,0001,402,341194,138Mar 08 05:23 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Option Exercise22.943,40077,9985,143Feb 09 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Option Exercise35.8865,0002,332,200538,187Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.0924,9791,775,656513,208Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.2440,0212,851,264473,187Jul 31 05:41 PM